phytonadione
Trade name: konakion
Approved
Sep 30, 1955
Phylloquinone is often called vitamin K1 or phytonadione. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants. Phylloquinone is also an antidote for coumatetralyl. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. MEPHYTON (Phytonadione tablets) are indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. MEPHYTON tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors II, VII, and X. Vitamin K is an essential cofactor for the gamma-carboxylase enzymes, which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX, and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors, which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms, which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria. Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine. In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function; that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors. MEPHYTON tablets generally exert their effect within 6 to 10 hours. — NCATS
Clinical trial activity
16 trials · 18 clinical orgs · 17 marketing orgs
Earliest trial started Jan 1, 2002 (NCT00150969)
Timeline
1950s
- Sep 30, 1955
Roche — Earliest FDA Approval
- Sep 30, 1955
Bausch Health Companies — NDA Secondary Org
- Sep 30, 1955
Roche — NDA Organization
1960s
- Jun 28, 1960
Teligent Pharmaceuticals — NDA Secondary Org
- Jun 28, 1960
Pharmaceutical Associates — Marketing Organization
- Jun 28, 1960
Pharmaceutical Associates — NDA Secondary Org
1970s
- Mar 1, 1976
International Medication — Marketing Organization
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
- May 11, 2018
Amneal Pharmaceuticals — Marketing Organization
- Feb 20, 2019
Zydus Discovery DMCC — Marketing Organization
- May 22, 2019
Dr. Reddy's Laboratories — Marketing Organization
2020s
- Apr 22, 2022
Cipla — Marketing Organization
- Jul 28, 2023
Sciegen Pharmaceticals — Marketing Organization
- Oct 12, 2023
Agnitio — Marketing Organization
- Dec 10, 2024
Gland Pharma Ltd — Marketing Organization
- Dec 19, 2024
Hikma — Marketing Organization
- Apr 17, 2025
Caplin Point Laboratories — Marketing Organization
- Sep 8, 2025
Alembic — Marketing Organization
Indications
Approved for
Studied for
- Atrial Fibrillation · Phase 2
- Blood Coagulation · Phase 3
- Bone Diseases · Phase 4
- Cardiovascular Diseases · Phase 3
- Crohn Disease · Phase 4
- Folliculitis · Phase 2
- Healthy Volunteers · Phase 1
- Hemorrhage · Phase 3
- Kidney Failure, Chronic · Phase 2
- Menopause · Phase 3
- Osteoarthritis · Phase 1/Phase 2
- Osteoporosis, Postmenopausal · Phase 3
- Thrombosis · Phase 3
Mechanism of action
Combination products
m.v.i. pediatric
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, biotin, panthenol, pyridoxine, riboflavin, vitamin a, ergocalciferol
vitape
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, pantothenic acid, biotin, pyridoxine, riboflavin, vitamin a, ergocalciferol
Approval history
- approvedPriority reviewSep 30, 1955
Chemistry & pharmacology
SMILES
CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O- Mol. weight
- 450.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaPhytomenadione ↗
- NCATSA034SE7857 ↗
- ChEMBLCHEMBL1550 ↗
- ChEMBLCHEMBL1201519 ↗
Also known as
- 2-methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
- 2-methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
- 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
- 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
- 3-phytylmenadione
- 3-phytylmenadione
- alpha-phylloquinone
- alpha-phylloquinone
- aquamephyton
- aquamephyton
- fitomenadiona
- fitomenadiona
- kanavit
- konakion
- konakion
- konakion mm
- konakion mm paed
- mephyton
- mephyton
- mephyton
- neokay
- orakay
- phyllochinon
- phyllochinon
- phytomenadionum
- phytonadione
- phytonadione
- phytonadione
- phytonadione
- phytonadione
- phytonadione
- phytylmenadione
- phytylmenadione
- phytylmenadione
- phytylmenaquinone
- vitamin k1
- vitamin k1
- vitamin k1
- vitamin k1
- vitamin k1
- vitamin k1
- vitamin k1
- vitamin k 1
- vitamin k 1
- α-phylloquinone
- α-phylloquinone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06385275 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Boston University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| NCT02259647 | N/A | Jun 1, 2014 | Institute of Liver and Biliary Sciences, India |
| NCT02324686 | Phase 2 | Jan 1, 2014 | University of Toronto |
| NCT01742273 | Phase 3 | Oct 1, 2013 | RWTH Aachen University |
| NCT01528800 | Phase 2 | Nov 1, 2012 | Dr. Rachel Holden, Queen's University, Belfast |
| NCT01474460 | N/A | Sep 1, 2011 | Department of Veteran Affairs |
| NCT01638182 | N/A | Mar 1, 2011 | Maastricht University |
| NCT00990158 | Phase 3 | Jul 1, 2010 | McMaster University, University of Western Ontario |
| NCT01094444 | Phase 2 | May 31, 2010 | University of Southern Denmark |
| NCT01194778 | N/A | Oct 1, 2009 | Maastricht University |
| NCT00905229 | N/A | May 1, 2009 | Emek Medical Center |
| NCT00794755 | Phase 3 | Nov 1, 2008 | University of Ottawa |
| NCT01235325 | Phase 4 | Jul 1, 2008 | Health Research Board, Ireland, National University of Ireland |
| NCT02256813 | Phase 1 | Sep 1, 2005 | Boehringer Ingelheim |
| NCT00143715 | Phase 3 | Sep 1, 2004 | McMaster University, University of Western Ontario |
| NCT00150969 | Phase 3 | Jan 1, 2002 | Canadian Institutes of Health Research (CIHR), University of Toronto |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maastricht University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| McMaster University | Academic/Hospital | 2 | 0 | 1 | 2004 |
| University of Toronto | Academic/Hospital | 2 | 2 | 2 | 2002 |
| University of Western Ontario | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2005 |
| Boston University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2011 |
| Dr. Rachel Holden | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Emek Medical Center | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Health Research Board, Ireland | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Institute of Liver and Biliary Sciences, India | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2024 |
| National University of Ireland | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Queen's University, Belfast | Academic/Hospital | 1 | 0 | 1 | 2012 |
| RWTH Aachen University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Ottawa | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Southern Denmark | Academic/Hospital | 1 | 1 | 1 | 2010 |
Marketing (23)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Agnitio | For profit | MKTG | Oct 12, 2023 |
| Alembic | For profit | MKTG | Sep 8, 2025 |
| Amneal Pharmaceuticals | For profit | MKTG | May 11, 2018 |
| Amneal Pharmaceuticals | For profit | SYN | Nov 4, 2025 |
| Bausch Health Companies | For profit | NDA2 | Sep 30, 1955 |
| Caplin Point Laboratories | For profit | MKTG | Apr 17, 2025 |
| Cipla | For profit | MKTG | Apr 22, 2022 |
| Dr. Reddy's Laboratories | For profit | SYN | May 22, 2019 |
| Dr. Reddy's Laboratories | For profit | MKTG | May 22, 2019 |
| Gland Pharma Ltd | For profit | MKTG | Dec 10, 2024 |
| Gland Pharma Ltd | For profit | SYN | Dec 10, 2024 |
| GlaxoSmithKline | For profit | MKTG | — |
| Hikma | For profit | MKTG | Dec 19, 2024 |
| Hospira | For profit | MKTG | Apr 6, 1983 |
| Hospira | For profit | NDA2 | Apr 6, 1983 |
| International Medication | For profit | MKTG | Mar 1, 1976 |
| Pharmaceutical Associates | For profit | MKTG | Jun 28, 1960 |
| Pharmaceutical Associates | For profit | NDA2 | Jun 28, 1960 |
| Roche | For profit | NDA | Sep 30, 1955 |
| Sciegen Pharmaceticals | For profit | MKTG | Jul 28, 2023 |
| Teligent Pharmaceuticals | For profit | NDA2 | Jun 28, 1960 |
| Zydus Discovery DMCC | For profit | MKTG | Feb 20, 2019 |
| Zydus Discovery DMCC | For profit | SYN | Feb 20, 2019 |